Literature DB >> 8645165

Multiple cis-trans conformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse-phase HPLC, CD and NMR spectroscopy.

K D O'Neal1, M V Chari, C H Mcdonald, R G Cook, L Y Yu-Lee, J D Morrisett, W T Shearer.   

Abstract

An eight-amino-acid synthetic peptide (IIe1-Phe2-Pro3-Pro4-Val5-Pro6-Gly7-Pro8) corresponding to the conserved proline-rich motif (PRM) of the intracellular domain of the prolactin receptor (PRL-R) was studied by one- and two-dimensional (1D and 2D) proton NMR spectroscopy in water and DMSO in order to characterize its conformational dynamics. The purified PRL-R PRM peptide eluted as two partially resolved peaks in equilibrium on reverse-phase HPLC (RP-HPLC) at 20 degrees C with a ratio of 60:40. At 30 degrees C, the two peaks coalesced into a single peak The two RP-HPLC peaks correspond to two peptide conformers resulting from the slow cis-trans isomerization of one of the four proline amide bonds. Although the peptide has only three amide (NH) protons, its ID NMR spectrum in water contains approximately 15 discernible NH region peaks, providing evidence for multiple conformers. The amide resonances were assigned on the basis of 2D-COSY spectra, chemical shift values resonance splitting patterns and temperature coefficients. The cis:trans ratio for each proline in water, calculated from integrated intensities and/or peak heights of the appropriate resonances, were Phe2-Pro3 (35:65), Pro3-Pro4 (40:60), Val5-Pro6 (70:30), and Gly7-Pro8 (30:70). Temperature studies (25-70 degrees C) were used to semi-quantitatively estimate the rates of isomerization for the different prolines. In water, Pro8 undergoes rapid isomerization; Pro3 isomerizes at an intermediate rate; while Pro4 and Pro6 both appear to isomerize very slowly since no coalescence of amide resonances was observed. In DMSO, only Pro4 displayed slow isomerization. Slow kinetics combined with a similar 60:40 ratio of conformers determined by RP-HPLC and NMR suggests that isomerization of the Pro3-Pro4 bond generates the two RP-HPLC peaks. Both proximal and distal proline isomerization effects were observed in NMR experiments. All of the 16 theoretical (24 = 16) proline configurations appear to exist in equilibrium in water The predominant (19%) conformation, trans3-trans4-cis6-trans8, may reflect the configuration of the PRM prolines in the native PRL-R. Isomerization of Pro6 from cis to trans generates an interaction between the peptide N-and C-termini, suggesting an overall pseudo-cyclic conformation. This all-trans proline configuration may play an important biochemical role in the function of cytokine/haematopoietin receptors. A model is proposed which suggests that isomerization of the PRM by an immunophilin such as the FK 506-binding protein (FKBP) serves as an on-off switch for cytokine receptor activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645165      PMCID: PMC1217282          DOI: 10.1042/bj3150833

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  69 in total

1.  Solution structure of the SH3 domain of Src and identification of its ligand-binding site.

Authors:  H Yu; M K Rosen; T B Shin; C Seidel-Dugan; J S Brugge; S L Schreiber
Journal:  Science       Date:  1992-12-04       Impact factor: 47.728

Review 2.  Chemistry and biology of the immunophilins and their immunosuppressive ligands.

Authors:  S L Schreiber
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

3.  Location of proline derivatives in conformational space. I. Conformational calculations; optical activity and NMR experiments.

Authors:  V Madison; J Schellman
Journal:  Biopolymers       Date:  1970       Impact factor: 2.505

4.  The proline-rich motif is necessary but not sufficient for prolactin receptor signal transduction.

Authors:  K D O'Neal; L Y Yu-Lee; W T Shearer
Journal:  Ann N Y Acad Sci       Date:  1995-09-07       Impact factor: 5.691

Review 5.  Cytokine signaling through nonreceptor protein tyrosine kinases.

Authors:  T Taniguchi
Journal:  Science       Date:  1995-04-14       Impact factor: 47.728

6.  Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase.

Authors:  S J Frank; G Gilliland; A S Kraft; C S Arnold
Journal:  Endocrinology       Date:  1994-11       Impact factor: 4.736

Review 7.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

8.  The proline-rich motif (PRM): a novel feature of the cytokine/hematopoietin receptor superfamily.

Authors:  K D O'Neal; L Y Yu-Lee
Journal:  Lymphokine Cytokine Res       Date:  1993-10

9.  Amino acids of the human growth hormone receptor that are required for proliferation and Jak-STAT signaling.

Authors:  Y D Wang; W I Wood
Journal:  Mol Endocrinol       Date:  1995-03

10.  Critical cytoplasmic domains of the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal transduction and tyrosine phosphorylation.

Authors:  K Sakamaki; I Miyajima; T Kitamura; A Miyajima
Journal:  EMBO J       Date:  1992-10       Impact factor: 11.598

View more
  10 in total

1.  Conformational state of a 25-mer peptide from the cyclophilin-binding loop of the HIV type 1 capsid protein.

Authors:  U Reimer; M Drewello; M Jakob; G Fischer; M Schutkowski
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

2.  Characterization of conantokin Rl-A: molecular phylogeny as structure/function study.

Authors:  Konkallu H Gowd; Maren Watkins; Vernon D Twede; Grzegorz W Bulaj; Baldomero M Olivera
Journal:  J Pept Sci       Date:  2010-08       Impact factor: 1.905

3.  Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling.

Authors:  K V Soman; B A Hanks; H Tien; M V Chari; K D O'Neal; J D Morrisett
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

4.  A CXCL8 receptor antagonist based on the structure of N-acetyl-proline-glycine-proline.

Authors:  Patricia L Jackson; Brett D Noerager; Michael J Jablonsky; Matthew T Hardison; Bryan D Cox; James C Patterson; Boopathy Dhanapal; J Edwin Blalock; Donald D Muccio
Journal:  Eur J Pharmacol       Date:  2011-03-31       Impact factor: 4.432

5.  A novel and functional interaction between cyclophilin A and prolactin receptor.

Authors:  Farhat Syed; Michael A Rycyzyn; Liz Westgate; Charles V Clevenger
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

6.  Influence of glycation on cis/trans isomerization and tautomerization in novel morphiceptin-related Amadori compounds.

Authors:  I Zigrović; J Kidric; S Horvat
Journal:  Glycoconj J       Date:  1998-06       Impact factor: 2.916

Review 7.  Molecular mechanisms of prolactin and its receptor.

Authors:  Charles L Brooks
Journal:  Endocr Rev       Date:  2012-05-10       Impact factor: 19.871

8.  The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8.

Authors:  Miklos Guttman; Neal N Padte; Yaoxing Huang; Jian Yu; Gabriel J Rocklin; Brian D Weitzner; Michele Scian; David D Ho; Kelly K Lee
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

9.  Orchestration of signaling by structural disorder in class 1 cytokine receptors.

Authors:  Pernille Seiffert; Katrine Bugge; Mads Nygaard; Gitte W Haxholm; Jacob H Martinsen; Martin N Pedersen; Lise Arleth; Wouter Boomsma; Birthe B Kragelund
Journal:  Cell Commun Signal       Date:  2020-08-24       Impact factor: 5.712

10.  Conformational Preferences and Antiproliferative Activity of Peptidomimetics Containing Methyl 1'-Aminoferrocene-1-carboxylate and Turn-Forming Homo- and Heterochiral Pro-Ala Motifs.

Authors:  Monika Kovačević; Mojca Čakić Semenčić; Kristina Radošević; Krešimir Molčanov; Sunčica Roca; Lucija Šimunović; Ivan Kodrin; Lidija Barišić
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.